Correction: Extended-release amphetamine (Dyanavel XR) is associated with reduced immediate-release supplementation in adults with ADHD, regardless of baseline patient variables: a retrospective cohort analysis of medical treatment records
Saved in:
| Main Authors: | Joel L. Young, Richard N. Powell, Anna Powell, Lisa L. M. Welling, Lauren Granata, Jaime Saal, Margot Nash |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | BMC Psychiatry |
| Online Access: | https://doi.org/10.1186/s12888-025-06903-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Extended-release amphetamine (Dyanavel XR) is associated with reduced immediate-release supplementation in adults with ADHD, regardless of baseline patient variables: a retrospective cohort analysis of medical treatment records
by: Joel L. Young, et al.
Published: (2025-01-01) -
Treatment of ADHD: Guanfacine Extended Release in ADHD
by: J Gordon Millichap, et al.
Published: (2014-08-01) -
Delusional Parasitosis in a Female Treated with Mixed Amphetamine Salts: A Case Report and Literature Review
by: Martha Buscarino, et al.
Published: (2012-01-01) -
Long-term dupilumab efficacy in type 2 asthma regardless of baseline characteristics
by: Michael E. Wechsler, et al.
Published: (2024-12-01) -
Challenges in amphetamine medication availability for individuals with ADHD: a narrative review of the current state of evidence
by: Mansour M. Alotaibi, et al.
Published: (2025-07-01)